• Tannaz Jamialahmadi, Maciej Banach, Wael Almahmeed, Prashant Kesharwani, and Amirhossein Sahebkar.
• Applied Biomedical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
• Arch Med Sci. 2022 Jan 1; 18 (5): 1372-1377.

IntroductionThis systematic review and meta-analysis focuses on PCSK9 changes in obese patients following bariatric surgery.MethodsA systematic literature search in four databases was performed. Comprehensive Meta-Analysis (CMA) V2 software used to conduct the meta-analysis. Studies were evaluated regarding heterogeneity in design, populations under investigation, and treatment duration using a random-effects model and the generic inverse variance weighting approach. A random-effect meta-regression approach was used to investigate the association with the estimated effect size.ResultsThe results of the meta-analysis on 4 trials including 260 individuals demonstrated a remarkable decline of PCSK9 after bariatric surgery (WMD = -57.34 ng/ml, 95% CI: -87.97, -26.71, p < 0.001; I 2 = 96.25%). Consistently, a significant decrease of LDL-C after bariatric surgery (WMD = -22.57 mg/dl, 95% CI: -27.5, -17.574, p < 0.001; I 2 = 86.35%) was observed.ConclusionsPCSK9 is reduced significantly after bariatric surgery. The decrease of PCSK9 might be utilized as an independent surrogate marker of improvement of atherosclerotic cardiovascular disease risk after bariatric surgery.Copyright: © 2022 Termedia & Banach.

5 keywords...

hide…